 WATERTOWN, Mass.--BUSINESS WIRE--Lyra Therapeutics, Inc. Nasdaq: LYRA, a clinical-stage therapeutics company leveraging its proprietary XTreoTM platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat ENT passages and other diseased tissues, today announced the successful outcome of an End-of-Phase 2 EOP2 meeting with the U.S. Food and Drug Administration FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis CRS. L 